Document Detail


Effect of verapamil in intermittent claudication A randomized, double-blind, placebo-controlled, cross-over study after individual dose-response assessment.
MedLine Citation:
PMID:  9008458     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The calcium antagonist verapamil is a vasodilator drug that has been shown to increase oxygen extraction of ischemic tissues in coronary and peripheral vascular disease. METHODS AND RESULTS: Since the balance between the positive and the negative effects of vasodilation may be delicate in ischemic diseases a dose-response study (dose range, 120 to 480 mg) was established to determine optimal, individual dosages of slow-release verapamil in 44 patients with stable intermittent claudication (Fontaine classification stage II) with respect to walking capacity. A randomized, double-blind, placebo-controlled, cross-over study (4 weeks) was performed to assess clinical and hemodynamic effects of verapamil. The optimal daily dose of verapamil on maximal walking ability was 120 (8 patients), 240 (8 patients), 360 (14 patients), and 480 mg (14 patients). Walking distances were measured at a metronome-controlled speed of 60 steps per minute on level surface. Optimal individual doses of verapamil increased mean pain-free walking distance by 29% from 44.9 to 57.8 meters (P < .01) and maximal walking distance by 49% from 100.7 to 149.8 meters (P < .001) compared with placebo. The increase in maximal walking distance correlated positively only with initial systolic ankle pressure (r = .49, P < .001) and ankle/brachial pressure index (r = .37, P < .013). Verapamil had no effect on systolic ankle pressure, ankle/brachial pressure index, peripheral leg temperature, or blood pressure, which suggests that the drug may have extrahemodynamic effects, possibly brought about through improved oxygen metabolism. CONCLUSIONS: Verapamil showed significant clinical benefits in patients with moderate intermittent claudication in this short-term study. Individual optimization of drug dosage should be considered an option both in trials and in the clinical setting in these patients.
Authors:
J P Bagger; P Helligsoe; F Randsbaek; H H Kimose; B S Jensen
Related Documents :
2931978 - Use of nifedipine as monotherapy in the management of hypertension.
3330988 - Double-blind, placebo-controlled trial of twice-daily nifedipine as a step-2 agent in m...
3370388 - Studies on the anti-vasoconstrictor activity of brl 34915 in spontaneously hypertensive...
7923458 - A comparison of nifedipine with methyldopa in pregnancy induced hypertension.
20374188 - Omega 3 polyunsaturated fatty acids supplementation and blood pressure levels in hypert...
10834718 - Resistance of pediatric and neonatal endotracheal tubes: influence of flow rate, size, ...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Circulation     Volume:  95     ISSN:  0009-7322     ISO Abbreviation:  Circulation     Publication Date:  1997 Jan 
Date Detail:
Created Date:  1997-02-27     Completed Date:  1997-02-27     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  411-4     Citation Subset:  AIM; IM    
Affiliation:
Vascular Surgery Unit, Aarhus University Hospital, Denmark.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Cross-Over Studies
Dose-Response Relationship, Drug
Double-Blind Method
Humans
Intermittent Claudication / drug therapy*,  physiopathology
Middle Aged
Placebos
Verapamil / therapeutic use*
Walking
Chemical
Reg. No./Substance:
0/Placebos; 52-53-9/Verapamil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Sex and test verification bias. Impact on the diagnostic value of exercise echocardiography.
Next Document:  Low-flow ischemia leads to translocation of canine heart GLUT-4 and GLUT-1 glucose transporters to t...